Loading...
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
Gupta, A Love, S Schuh, A Shanyinde, M Larkin, J Plummer, R Nathan, P Danson, S Ottensmeier, C Lorigan, Paul C
Gupta, A
Love, S
Schuh, A
Shanyinde, M
Larkin, J
Plummer, R
Nathan, P
Danson, S
Ottensmeier, C
Lorigan, Paul C
Citations
Altmetric:
Abstract
Treatment options for wild-type BRAF melanoma patients remain limited. Selumetinib, a MEK 1/2 inhibitor, suppresses pERK levels independent of BRAF and NRAS mutation status, and combination with docetaxel has demonstrated synergy in xenograft models. The aim of this study was to assess the efficacy and safety of selumetinib plus docetaxel as first-line treatment in patients with wild-type BRAF advanced melanoma.
Description
Date
2014-05
Publisher
Collections
Files
Loading...
Main article
Adobe PDF, 186.81 KB
Keywords
Type
Article
Citation
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. 2014, 25 (5):968-74 Ann Oncol